Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00379418 · ClinicalTrials.gov registry record
Anti Ischemic Effects of Abciximab in Angioplasty and Stenting Patients
A clinical trial, sponsored by Emory University.
- Completed
- Registry status
- 220
- Enrollment target
NCT00379418 is a clinical trial that has completed, run by Emory University. The registered enrollment target is 220 participants.
The verdict
NCT00379418 has completed, sponsored by Emory University.
- COMPLETED
- Registry status
- 220 participants
- Enrollment target
Study Summary
AIR STUDY TITLE: Anti-Ischemic effects of Abciximab(Reopro) PATIENT POPULATION: Patients undergoing PCI(an interventional procedure placing a small stent/metallic tube to keep a narrowed artery in your heart open) and either on a stable statin dose or not on a statin. Statin= cholesterol lowering drug(ie, lipitor, zocor). INTERVENTION: Heparin vs. heparin + abciximab during PCI PURPOSE: Measure the effects of abciximab on special healing blood stem cells (EPC's-Endothelial Progenitor Cells), on inflammation, on oxidative stress and on microvascular blood flow. PATIENT ASSESSMENT: 1. 50ccs blood draw on day 1(from sheath), day 2 ,day 7 and day 28. 2. Measurement of blood flow in selected suitable patients 3. 10 minute questionnaire before discharge and on visit on day 28.
Interventions
- DRUG Abciximab
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 220 participants |
| Start Date | 2003-01 |
| Est. Completion | 2009-12 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00379418
The ClinicalTrials.gov registry entry for NCT00379418 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 220 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Emory University, which has 1,208 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Abciximab is the first listed.
NCT00379418 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00379418 about?
NCT00379418 is a clinical study titled "Anti Ischemic Effects of Abciximab in Angioplasty and Stenting Patients". AIR STUDY TITLE: Anti-Ischemic effects of Abciximab(Reopro) PATIENT POPULATION: Patients undergoing PCI(an interventional procedure placing a small stent/metallic tube to keep a narrowed artery in your heart open) and either on a stable statin dose or not on a statin. Statin= cholesterol lowering ...
What is the current status of trial NCT00379418?
This trial is currently completed. The enrollment target is 220 participants. The study started on 2003-01. Estimated completion is 2009-12.
What interventions are being tested in trial NCT00379418?
The interventions under investigation include: Abciximab (DRUG).
Who is sponsoring clinical trial NCT00379418?
This trial is sponsored by Emory University, which has 1,208 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.